193152-99-7

Upstream product

• 28188-41-2 m-(bromomethyl)benzonitrile 
• 1263065-69-5 C₇H₆O₂*C₁₃H₁₆N₂O₂ 
• 4385-76-6 4-(4-pyridinyl)benzoic acid 
• 193152-96-4 (2R,3R)-3-Amino-2-(3-cyano-benzyl)-butyric acid methyl ester 

Downstream Products

• 409081-12-5 (2R,3R)-2-(3-carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl)benzoylamino]-butyric acid methyl ester hydrochloride 
• 1401901-15-2 methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate benzoate 
• 193153-02-5 (2R,3R)-2-(3-Cyano-benzyl)-3-[4-(1-oxy-pyridin-4-yl)-benzoylamino]-butyric acid methyl ester 

Relevant academic research and scientific papers

Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients

The invention relates to the use of (2R,3R)-2-(3-carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl)benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in non-ST elevation myocardial infarction, said treatment comprising administering a therapeutically effective amount of (2R,3R)-2-(3-Carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl)benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof to a human patient, who is elderly and/or shows renal insufficiency and/or has a low body weight.

OTAMIXABAN FOR USE IN THE TREATMENT OF NON-ST ELEVATION ACUTE CORONARY SYNDROME IN PATIENTS PLANNED TO UNDERGO CORONARY ARTERY BYPASS GRAFTING

The invention relates to otamixaban or a pharmaceutically acceptable salt thereof for use in the treatment of non-ST elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting.

BENZOIC ACID SALT OF OTAMIXABAN

The invention relates to a benzoic acid salt of methyl (2R,3R)-2-{3-[amino (imino) methyl]benzyl}-3-{[4-(1 -oxidopyridin-4-yl)benzoyl]amino}butanoate, and to a benzoic acid salt of methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1 -oxidopyridin-4- yl)benzoyl]amino}butanoate which is in a crystalline form or in at least partially crystalline form, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity.

Further optimization of the beta-aminoester class of factor Xa (fXa) inhibitors is described culminating in the identification of 9c (FXV673), a potent and selective factor Xa inhibitor with excellent in vivo anticoagulant activity. An X-ray structure of FXV673 bound to human fXa is also presented. Based on its selectivity, potent in vivo activity and favorable pre-clinical safety profile, FXV673 was selected for further development and is currently undergoing clinical trials.